{"id":"a-zoster-mrna-vaccine-sys6017","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine delivers mRNA encoding immunogenic VZV proteins, which are translated intracellularly to present viral epitopes to the immune system. This triggers both CD8+ T-cell and antibody responses to prevent or reduce the severity of herpes zoster (shingles) infection. The mRNA-based platform allows rapid manufacturing and potentially improved immunogenicity compared to traditional inactivated vaccines.","oneSentence":"SYS6017 is an mRNA vaccine that encodes varicella-zoster virus (VZV) antigens to stimulate adaptive immune responses against herpes zoster.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:03.425Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of herpes zoster (shingles) in adults"}]},"trialDetails":[{"nctId":"NCT07354659","phase":"PHASE2","title":"Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-01-10","conditions":"Herpes Zoster","enrollment":800},{"nctId":"NCT06954818","phase":"PHASE1","title":"Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-05-10","conditions":"Herpes Zoster","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"A zoster mRNA vaccine SYS6017","genericName":"A zoster mRNA vaccine SYS6017","companyName":"CSPC Megalith Biopharmaceutical Co.,Ltd.","companyId":"cspc-megalith-biopharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"SYS6017 is an mRNA vaccine that encodes varicella-zoster virus (VZV) antigens to stimulate adaptive immune responses against herpes zoster. Used for Prevention of herpes zoster (shingles) in adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}